Treatment

Treatment is determined by the type and stage of cancer, as well as by what treatments and services a patient chooses. The guidelines and other documents available here focus on topics related to the treatment of cancer in Ontario.

Multidisciplinary Cancer Conferences

Displaying Guidelines

166 Items

2019 Antiemetic Recommendations for Chemotherapy-Induced Nausea and Vomiting: A Clinical Practice Guideline

Document Status: Current
ID: GL-C50-09

Jun 2019

Active Surveillance for the Management of Localized Prostate Cancer

Document Status: Current
ID: 17-9

Dec 2014

Acute Leukemia Provincial Plan

Document Status: Current
ID: GL-C50-34

Aug 2017

Adjuvant Care for Stage I Ovarian Cancer

Document Status: Current
ID: 4-13
Version: 3

Mar 2022

Adjuvant Systemic Chemotherapy for Stage II and III Colon Cancer Following Complete Resection

Document Status: Current
ID: 2-29
Version: 4

Updated

Feb 2024

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

Document Status: Current
ID: GL-7-A-2016-3

Apr 2017

Adult Acute Leukemia Services Plan for the Greater Toronto Area - Recommendations Report

Document Status: Current
ID: GL-C50-02

Jan 2012

Adult Sarcoma Management in Ontario

Document Status: Current
ID: GL-C50-04-V2
Version: 2

Jan 2009

An Endorsement of the 2021 Cancer Care Alberta Clinical Practice Guideline on Uveal Melanoma

Document Status: Current
ID: C50-CIDAP-1

Updated

Mar 2024

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Document Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

An Endorsement of the 2021 Guideline on the Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update

Document Status: Current
ID: GL END 3-23
Version: N/A

Oct 2021

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Document Status: Current
ID: GL-END-C50-35

Aug 2023